Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 636 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Hepion Pharmaceuticals Inc | HEPA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.49 | 07:00:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.49 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 636 | - | 1.22 - 20.66 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:01:14 | formt | 632 | $ 1.49 | USD |
Hepion Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.46M | 4.34M | - | 0 | -45.34M | -10.45 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Hepion Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEPA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.09 | 2.21 | 1.22 | 1.62 | 115,012 | -0.60 | -28.71% |
| 1 Month | 2.26 | 2.8999 | 1.22 | 2.00 | 56,043 | -0.77 | -34.07% |
| 3 Months | 1.82 | 3.4899 | 1.22 | 2.20 | 81,818 | -0.33 | -18.13% |
| 6 Months | 4.40 | 5.2999 | 1.22 | 2.66 | 73,711 | -2.91 | -66.14% |
| 1 Year | 14.40 | 20.66 | 1.22 | 12.73 | 148,850 | -12.91 | -89.65% |
| 3 Years | 34.60 | 46.368 | 1.22 | 26.86 | 532,887 | -33.11 | -95.69% |
| 5 Years | 62.20 | 167.00 | 1.22 | 45.74 | 1,024,884 | -60.71 | -97.60% |
Hepion Pharmaceuticals Description
| Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. |
